Analysts expect GT Biopharma to report zero revenue and a consensus loss per share of $2.50 for Q3 2026, with the current $3.96 stock price trading at a deep discount to the $76.50 average analyst target.
The primary focus for investors is the clinical development of the company’s TriKE platform, particularly enrollment updates and preliminary data for lead candidates GTB-3650 and GTB-5550.
Recent presentations at the SITC 2026 Annual Meeting highlighted the platform's utility in solid tumors, while a September financing update extended the company's cash runway into Q3 2027. Investors are closely monitoring the Phase 1 dose-escalation trials for any signals of efficacy in hematologic malignancies and multiple myeloma.